To support all the stakeholders involved in this exciting journey of biosimilars in the US, Samsung Bioepis will bring you this Samsung Bioepis Biosimilar Market Report.

The Samsung Bioepis Biosimilar Market Report will be published quarterly in conjunction with the release of the CMS ASP file. In the 1 st edition of the Samsung Bioepis Biosimilar Market Report, we provide an in-depth analysis of pricing and market share trends in the US market and for the following biosimilar categories:
Oncology / Supportive Care / Immunology / Ophthalmology / Endocrinology
 
 

We will also review the topic of biologic interchangeability and its implications for the biosimilar market moving forward.

Each subsequent issue of the Samsung Bioepis Biosimilar Market Report will provide a complete overview of the latest pricing and utilization trends for the entire biosimilar market along with a review of the most important topics in the biosimilar sphere.

We invite you to download our first Samsung Bioepis Biosimilar Market Report Here:
CMS: Centers for Medicare & Medicaid Services; ASP: Average Sales Price
†: ASP discounted % vs. reference product ASP when first biosimilar in class launch
1: Based on internal analysis by SAMSUNG BIOEPIS CO., LTD. using data from the following source: IQVIA MIDAS® in Standard Units for the period
Jan 2017 – Dec 2022 reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. 2: Medicare part B Drug Average Sales Price. CMS. (Mar 2023).
© 2023 Samsung Bioepis Co., Ltd. All Rights Reserved. 4/2023. [SB_2023_04_05_067_P]